Summary of p53 mutations detected in plasma of cancer patients with non-metastatic disease a.

aThe literature was reviewed for English language publications that provided the following information: (1) tumor stage: only non-metastatic tumors, Stages I-III, were included (for colorectal cancer, modified Dukes Stages A�CC); (2) the number of tumor samples with identified p53 mutations; (3) the number of corresponding plasma DNA samples that were positive for the same personalized p53 mutation detected in the tumor. The literature review included publications cited within Fleischhacker and Schmidt (2007).bReferences:Andriani F et al. (2004).Int J Cancer108: 91�C96.Bazan V et al. (2006).Ann Oncol17 Suppl 7: vii84�Cvii90.Gonzalez R et al. (2000).Ann Oncol11: 1097�C1104.Hibi K et al. (1998).Cancer Res58: 1405�C1407.Mayall F et al.(1998). J Clin Pathol51: 611�C613.Otsuka J et al. (2004). Int J Gynecol Cancer14: 459�C464.Swisher EM et al. (2005). Am J Obstet Gynecol193: 662�C667.Wang Q et al. (2003). Int J Cancer106: 923�C929.cMutations were detected in serum, rather than plasma.dMutations were detected in serum or plasma.

a. 本研究针对英文发表文献开展系统综述，纳入同时满足以下三项信息的研究：(1) 肿瘤分期：仅纳入非转移性I~III期肿瘤（结直肠癌患者采用改良Dukes分期A~C期）；(2) 携带明确p53突变的肿瘤样本数量；(3) 检测到与肿瘤中检出的同一个性化p53突变呈阳性的对应血浆DNA（plasma DNA）样本数量。本次综述纳入了Fleischhacher与Schmidt (2007) 引用的相关文献。
b. 参考文献：
Andriani F 等(2004). 《国际癌症杂志（Int J Cancer）》, 108: 91–96.
Bazan V 等(2006). 《肿瘤学年鉴（Ann Oncol）》, 17 增刊7: vii84–vii90.
Gonzalez R 等(2000). 《肿瘤学年鉴（Ann Oncol）》, 11: 1097–1104.
Hibi K 等(1998). 《癌症研究（Cancer Res）》, 58: 1405–1407.
Mayall F 等(1998). 《临床病理学杂志（J Clin Pathol）》, 51: 611–613.
Otsuka J 等(2004). 《国际妇科癌症杂志（Int J Gynecol Cancer）》, 14: 459–464.
Swisher EM 等(2005). 《美国妇产科杂志（Am J Obstet Gynecol）》, 193: 662–667.
Wang Q 等(2003). 《国际癌症杂志（Int J Cancer）》, 106: 923–929.
c. 突变检出样本为血清，而非血浆。
d. 突变可在血清或血浆中检出。